Elevated Expression of Glycerol-3-Phosphate Phosphatase as a Biomarker of Poor Prognosis and Aggressive Prostate Cancer

The limitations of the biomarker prostate-specific antigen (PSA) necessitate pursuit biomarkers capable better identifying high-risk prostate cancer (PC) patients in order to improve their therapeutic management and outcomes. Aggressive tumors characteristically exhibit high rates glycolysis lipogenesis. Glycerol 3-phosphate phosphatase (G3PP), also known as phosphoglycolate (PGP), is a recently identified mammalian enzyme, shown play role regulation glucose metabolism, lipogenesis, lipolysis, cellular nutrient-excess detoxification. We hypothesized that G3PP may relieve metabolic stress cells assessed association its expression with PC patient prognosis. Using immunohistochemical staining, we epithelial two different radical prostatectomy (RP) cohorts total 1797 patients, for whom information on biochemical recurrence (BCR), metastasis, mortality was available. between expression, bone cancer-specific survival established using log-rank multivariable Cox regression analyses. High associated an increased risk BCR, PC-specific mortality. Multivariate analysis revealed independent predictor BCR metastasis development. from eligible prostatectomies new prognostic poor prognosis aggressive recurrence,